TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

Bottom Line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient’s risk of hepatocellular carcinoma (HCC), ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

The dogs are detecting changes in volatile organic compounds — substances produced by the body when diseases like cancer are ...